SHH and pancreatic neoplasm: Failure of Smoothened inhibitors in clinical trials in patients with metastasis further confirms that inhibition of canonical Hh signaling alone is not sufficient to reduce pancreatic cancer progression, and indicates that paracrine Shh signaling has a very different role from Hh signaling in the cancer cells.